Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535583 | 0.89 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3536375 | 0.89 | PRKDC (1.00) | PRKDC | |
| SCHEMBL31061551 | 0.89 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3536307 | 0.89 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3535165 | 0.87 | PRKDC (1.00) | PRKDC | |
| SCHEMBL13461749 | 0.87 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3539003 | 0.85 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3545355 | 0.84 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3539949 | 0.82 | PRKDC (1.00) | PRKDC | |
| SCHEMBL3537736 | 0.82 | PRKDC (1.00) | PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| EP-1417196-A1 | DNA-PK INHIBITORS | Cancer Research Technology Limited (GB) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003024949-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885 |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | PRKDC 2551/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.